Literature DB >> 36114430

Formulation of Topical Flurbiprofen Solid Lipid Nanoparticle Gel Formulation Using Hot Melt Extrusion Technique.

Arvind Bagde1, Emmanual Kouagou1, Mandip Singh2.   

Abstract

Hot melt extrusion (HME) has been used for the formulation of topical solid lipid nanoparticle (SLN) gel without using any other size reduction technique including high pressure homogenization or sonication. SLN formulation solely using HME has not been applied to other drugs except IBU. Therefore, the purpose of the present study was to formulate FLB SLN solely using HME technique and evaluate the SLN formulation in inflammation animal model. Stable 0.5% w/v FLB SLN gel with particle size < 250 nm, PI < 0.3 and EE of > 98% was prepared. Differential scanning calorimetry (DSC) thermogram showed that the drug was converted to amorphous form in the HME process. Additionally, rheological studies demonstrated that FLB SLN gel and marketed FLB gel showed shear thinning property. FLB SLN formulation showed significantly (p < 0.05) higher peak force required to spread the formulation as compared to marketed FLB formulation. Stability studies showed that FLB SLN gel was stable for a month at room temperature and 2-4°C. Moreover, in vitro permeation test (IVPT) and ex vivo skin deposition study results revealed that FLB SLN gel showed significant (p < 0.05) increase in drug deposition in dermal layer and drug permeation as compared to control marketed formulation. Further, in vivo anti-inflammatory study showed equivalent inhibition of rat paw edema using 0.5% w/v FLB SLN gel which has 10 times less strength compared to control formulation. Overall, FLB SLN formulation was successfully manufactured solely using HME technique which resulted in enhanced the skin permeation of FLB and superior anti-inflammatory activity.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Entities:  

Keywords:  Flurbiprofen (FLB); HME; SLN; topical formulation

Mesh:

Substances:

Year:  2022        PMID: 36114430     DOI: 10.1208/s12249-022-02410-w

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   4.026


  37 in total

1.  The production and characteristics of solid lipid nanoparticles (SLNs).

Authors:  DongZhi Hou; ChangSheng Xie; KaiJin Huang; ChangHong Zhu
Journal:  Biomaterials       Date:  2003-05       Impact factor: 12.479

2.  Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment.

Authors:  M Singh; A J Ferdous; T L Jackson
Journal:  J Control Release       Date:  1999-05-01       Impact factor: 9.776

3.  EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.

Authors:  Apurva R Patel; Mahavir Chougule; Mandip Singh
Journal:  Pharm Res       Date:  2014-05-29       Impact factor: 4.200

4.  Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.

Authors:  Ketan Patel; Ravi Doddapaneni; Nusrat Chowdhury; Cedar Ha Boakye; Gautam Behl; Mandip Singh
Journal:  Nanomedicine (Lond)       Date:  2016-05-12       Impact factor: 5.307

5.  Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.

Authors:  Cedar H A Boakye; Ketan Patel; Mandip Singh
Journal:  Int J Pharm       Date:  2015-04-21       Impact factor: 5.875

6.  Chapter 9 - Nanoliposomal dry powder formulations.

Authors:  Gaurang Patel; Mahavir Chougule; Mandip Singh; Ambikanandan Misra
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

7.  Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.

Authors:  Madhu Sudhan Shaik; Abhijit Chatterjee; Mandip Singh
Journal:  J Pharm Pharmacol       Date:  2004-07       Impact factor: 3.765

8.  Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer.

Authors:  Ravi Doddapaneni; Ketan Patel; Ibtisam Hasan Owaid; Mandip Singh
Journal:  Drug Deliv       Date:  2015-12-24       Impact factor: 6.419

9.  Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.

Authors:  Ketan Patel; Ravi Doddapaneni; Vasanthakumar Sekar; Nusrat Chowdhury; Mandip Singh
Journal:  Mol Pharm       Date:  2016-04-26       Impact factor: 4.939

10.  Design, synthesis of novel lipids as chemical permeation enhancers and development of nanoparticle system for transdermal drug delivery.

Authors:  Srujan Marepally; Cedar H A Boakye; Punit P Shah; Jagan Reddy Etukala; Adithi Vemuri; Mandip Singh
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.